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23 Abstract 
24 Disorders of sex development (DSDs) are a diverse group of conditions where the chromosomal, 
25 gonadal or anatomical sex can be atypical. The highly heterogeneous nature of this group of 
26 conditions often makes determining a genetic diagnosis challenging. Prior to Next Generation 
27 Sequencing (NGS) technologies, genetic diagnostic tests were only available for a few of the many 
28 DSD associated genes, which consequently had to be tested sequentially. Genetic testing is key in 
29 establishing the diagnosis, allowing for personalised management of these patients. Pinpointing the 
30 molecular cause of a patients DSD can significantly impact patient management by informing future 
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231 development needs, altering management strategies and identifying correct inheritance pattern when 
32 counselling family members.
33 We have developed a 30 gene NGS panel, designed to be used as a frontline test for all suspected 
34 cases of DSD (both 46,XX and 46,XY cases). We have confirmed a diagnosis in 25 of the 80 patients 
35 tested to date. Confirmed diagnoses were linked to mutations in AMH, AMHR2, AR, HSD17B3, 
36 HSD3B2, MAMLD1, NR5A1, SRD5A2 & WT1 which have resulted in changes to patient 
37 management. The minimum diagnostic yield for patients with 46,XY DSD is 25/73.  In 34/80 patients 
38 only benign or likely benign variants were identified, and in 21/80 patients only variants of uncertain 
39 significance, (VOUS) were identified, resulting in a diagnosis not being confirmed in these individuals. 
40 Our data supports previous studies, that an NGS panel approach is a clinically useful and cost 
41 effective frontline test for patients with DSDs.  
42
43  Introduction
44 Disorders of sex development (DSD) encompass a wide range of conditions with diverse clinical 
45 features, pathophysiology and clinical management13. The recently revised stratified DSD diagnostic 
46 pathway consists of clinical examination, biochemical investigations and karyotype determination4,5. 
47 Once a presumptive diagnosis has been made, targeted sequencing of candidate genes may then be 
48 performed at a later stage5. Whilst reaching the correct diagnosis impacts significantly on 
49 management decisions, determining the aetiology of genital ambiguity in patients with DSD on the 
50 basis of clinical and biochemical assessment remains challenging6. In DSD where no clear 
51 abnormality in the steroidogenesis pathway is present, the yield from genetic testing had historically 
52 remained low, and with single-gene sequencing was both costly and time consuming4. 
53 Improvements in gene sequencing technology in conjunction with rapidly falling costs have led to the 
54 use of targeted next-generation sequencing (NGS) assays. These enable multiple known disease 
55 causative genes to be sequenced in parallel alongside initial clinical assessment and biochemical 
56 investigations, potentially avoiding the need for additional expensive biochemical and radiological 
57 investigations7.  Reaching a timely diagnosis is extremely important as it ends diagnostic uncertainty, 
58 avoids further unnecessary investigations, enables appropriate disease-specific counseling (including 
59 assessment of future fertility potential and malignancy risk) and implementation of personalised 
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360 medical plans in accordance with current disease specific consensus guidelines8. Additionally, in the 
61 long-term accurate early diagnosis will support the development of better designed outcome studies.
62 The use of targeted next generation sequencing panels for molecular diagnosis of DSD patients has 
63 already been reported successfully in several previous publications912.  These publications show 
64 diagnostic yield and clinical utility in predominantly 46,XY DSD cohorts using panels of 64-219 genes.  
65 We present our data showing sequence analysis of a cohort of 80 DSD patients using a 30 gene 
66 panel.
67 Materials & Methods
68 Patients
69 Eighty patients with a DSD were referred to the West Midlands Regional Genetics Laboratory 
70 (WMRGL) at the Birmingham Womens and Childrens NHS Foundation Trust for diagnostic DSD 
71 testing between March 2014 and March 2017, comprising of 73 patients with 46,XY DSD and 7 with 
72 46,XX DSD. Referrals were from Clinical Genetics, Urology or Endocrinology specialists. Karyotyping 
73 and/or microarray results were typically available to confirm the patients karyotype. Single gene 
74 testing may have also been performed in advance of the NGS screen but a pathogenic mutation had 
75 not been identified. Where DNA was available, cascade testing was performed on parental or sibling 
76 samples to confirm segregation or to confirm a diagnosis in the probands similarly affected siblings. 
77 Data from cascade testing is not included here; all figures therefore represent only probands referred 
78 for diagnostic testing who underwent analysis via the NGS panel. Consent was obtained for clinical 
79 testing from all patients in this study. Patients undertaking routine clinical testing in this report are not 
80 identifiable. This report has been registered with the audit committee at the Birmingham Womens and 
81 Children Hospital NHS Foundation trust (CARMS-30120).
82 Gene selection
83 Thirty genes with a reported clinical association with a DSD were selected following discussion 
84 between the WMRGL and clinical specialists in Genetics and Endocrinology (table 1).  Genes include 
85 those thought to be involved in 46,XY DSD and 46,XX DSD, and are tested as a single panel pipeline 
86 covering both of these groups of patients. The CYP21A2 gene associated with 95% of cases of 
87 Congenital Adrenal Hyperplasia (CAH) is not included in this panel. This is because this patient group 
88 typically have a clinical diagnosis prior to genetic testing, and also the CYP21A2 pseudogene makes 
89 accurate mapping of short reads to the functional gene very difficult. 
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490 Sample preparation
91 Genomic DNA was typically extracted from peripheral blood samples using Qiasymphony technology 
92 (Qiagen) following the manufacturers instructions. The concentration of all genomic DNA samples 
93 were assessed using a Qubit (Life technologies) prior to sequencing.
94 Next Generation Sequencing (NGS)
95 Library preparation was initially performed by a customised TruSeq Custom Amplicon (TSCA, Illumina 
96 Inc, San Diego, California) 30 gene panel run on the MiSeq (Illumina Inc, San Diego).  Exons were 
97 targeted with 25 base pairs of padding on either side, resulting in 431 amplicons of 425bp. 
98 Enrichment was performed on 250ng of genomic DNA, and sequencing using 250 base paired-end 
99 reads. TruSight One (TSO) technology was then used to capture exonic regions of 4,813 genes, 
100 sequencing 24 samples on a HiSeq 2500 (Illumina Inc, San Diego, California). The same 30 DSD 
101 genes were analysed as a virtual panel using TSO.  A depth of coverage of 20x was considered 
102 sufficient for either approach, and a technical report was generated indicating the proportion of each 
103 gene covered to this level. All patients that were initially run by TSCA but where a diagnosis was not 
104 confirmed were subsequently retested using TSO. NGS was performed on probands only and 
105 analysis for copy number variation in these genes was not performed. 
106 Bioinformatic analysis
107 Bioinformatic analysis was performed using an in-house pipeline where sequence reads were 
108 mapped to the human genome hg19 reference. Several programmes are incorporated in the pipeline; 
109 Trimmomatic (quality trimming of reads), BWA mem (alignment to hg19), Samblaster (duplicate 
110 marking), Abra (realigning), Platypus (variant calling), Annovar (variant annotation) PLINK (IBS 
111 calculation) and Picard (calculating hybridisation and mapping metrics). Custom python code and 
112 bedtools were used to calculate coverage and the Python module pandas to produce patient specific 
113 Excel files. 
114 Variant interpretation and reporting
115 Variants were classified following the Association of Clinical Genetic Science (ACGS, 
116 www.acgs.uk.com) best practice guidelines, based on the American College of Medical Genetics and 
117 genomics recommendations13. This included utilisation of in-house frequency data, population 
118 frequency data (dbSNP, 1000 genomes & EXAC), in-silico tools including Polyphen, Align GVGD and 
119 splice tools (searched through the alamut interface), the Human Gene Mutation Database (HGMD 
120 Professional, Biobase Corporation), and evidence from peer-reviewed literature. The five classes are 
121 described in table 2. For suspected compound heterozygous mutations, parental samples were 
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5122 requested to confirm that the mutations were on opposite alleles (in trans). Regions of interest were 
123 all exonic regions plus 30bp upstream and 10bp downstream of each exon. Intronic variants outside 
124 of these regions were considered as deep intronic variants (DIVs) and no further investigation was 
125 undertaken.  In some cases, Sanger sequencing was performed to complete gene coverage to a 
126 depth of 20x. For example, where a single heterozygous mutation in a likely candidate gene 
127 associated with a recessive condition had been identified.
128
129 Results
130 The DSD NGS panel provided a molecular diagnosis in 25 out of the 80 patients tested (table 3). A 
131 diagnosis was deemed as confirmed where variants of class 4 or class 5 were identified which were 
132 consistent with the inheritance pattern for that gene, and where disruption of the gene was in keeping 
133 with the patients phenotype. On 4 occasions a class 3 variant was found in combination with a class 
134 5 mutation (patients 2, 11, 15 & 20). Although technically class 3 variants are of uncertain 
135 significance, their presence in combination with a class 5 variant in these patients, when considered 
136 with the clinical information provided led us to believe that these findings were causally related to the 
137 clinical features. The overall diagnostic yield for this panel is therefore currently 25/80 for all samples 
138 and 25/73 for 46,XY DSD. This figure represents the likely minimum detection rate of this panel as 
139 some samples were received with an initial request for Sanger sequencing of a specific gene, and 
140 typically only included for panel testing if negative on Sanger sequencing. 
141
142 Class 3 variants (listed in table 4) were typically missense mutations which had not been previously 
143 reported, and therefore no clinical information was available. These were included in the clinical report 
144 with a statement that a diagnosis had not been confirmed due to the uncertainty around the 
145 pathogenicity of such variants. Where only class 1 and/or 2 variants were identified, patient reports 
146 stated that no evidence of a pathogenic mutation had been identified. A summary of the findings can 
147 be seen in figure 1. Both previously reported and novel pathogenic mutations and variants were 
148 identified in AMH, AMHR2, AR, DHCR7, HSD17B3, HSD3B2, LHCGR, MAMLD1, NR5A1, SRD5A2 
149 and WT1 (table 5). Diagnosis due to mutations in the AR gene (7 patients) were the most commonly 
150 observed (table 3) followed by diagnosis due to HSD17B3 (5 patients) and SRD5A2 (4 patients).  
151
152 Discussion
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6153 DSDs, estimated to be present in 1.7% of live births14 are a diagnostic challenge due to variable 
154 expressivity and pleiotrophy, clinical overlap of the different DSD, and their significant aetiological 
155 heterogeneity. Historically a genetic diagnosis was made in as few as 13% of cases 15. We present 
156 data from 80 patients who underwent routine diagnostic testing for DSD using a 30 gene NGS panel. 
157 This diagnostic DSD panel was utilised irrespective of clinical and biochemical features, unless a 
158 specific single Sanger sequence request was made based on phenotypic assessment. The diagnostic 
159 yield of this DSD panel was shown to be 25/80 for all DSDs, higher for 46,XY DSD (25/73), and  
160 would have been higher in this cohort if all cases with a suspected diagnosis, (all subsequently 
161 confirmed on Sanger Sequencing) , had not been filtered out  prior to implementation of the panel 
162 test. Pathogenic (or likely pathogenic) mutations in the AMH, AMHR2, AR, HSD17B3, HSD3B2, 
163 MAMLD1, NR5A1, SRD5A2 and WT1 genes were identified. Our detection rate and findings are 
164 similar to previous studies, summarised in Table 6.  Dong et al demonstrated an increased detection 
165 rate of 9/13 in 46,XY DSD patients using a panel of 219 genes10, however the study included small 
166 patient numbers and so may not be representative.  
167
168 Separating out analysis of 46,XY DSD from those with 46,XX DSD results in an improved 46,XY yield 
169 to 25/73 but highlights the 0/7 diagnostic yield of individuals with a 46,XX DSD. Difficulty in confirming 
170 a molecular diagnosis in those with an 46,XX DSD has also been seen in other studies11,12. Sample 
171 numbers for those with 46,XX DSD are very small in this study and therefore are unlikely to be 
172 representative of the true diagnostic capability of the panel for these patients. In addition, other 
173 causes of 46,XX DSD such as translocation of SRY to the X chromosome, duplications of SOX9 or 
174 CAH due to CYP21A2 deficiency are not detectable by this method. Patients would typically have had 
175 karyotype and/or microarray prior to testing on the panel and would have been tested separately for 
176 CYP21A2 deficiency if CAH was suspected. Increased sample numbers and incorporation of more 
177 46,XX DSD associated genes as they are identified may allow a more accurate estimate of the 
178 panels usefulness for those with 46,XX DSD. It will also be important to include new 46,XX DSD 
179 genes that are likely to be identified in current international exome/genome sequencing projects such 
180 as the 100,000 genome project in England.16 
181
182 Novel mutations and variants in several genes were identified where functional studies were not 
183 available. Variants were considered likely to be causative if they were observed in trans (on opposite 
184 chromosome alleles) with a known pathogenic mutation, in a disease gene showing autosomal 
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7185 recessive inheritance (4 patients in our cohort). In some cases, segregation studies confirming the bi-
186 allelic nature of the findings also supported a likely pathogenic role. This information has expanded 
187 our knowledge of likely diagnostic DSD variants for future investigation of DSD patients. Novel VOUS 
188 in the absence of a confirmed diagnosis were also seen. Whilst their significance currently remains 
189 uncertain, wider data sharing through publication of studies such as this is crucial to further our 
190 understanding of such variants. The large number of VOUS in this cohort is predominantly due to 
191 limited clinical information related to some DSD related genes, for example only VOUS were detected 
192 in the CBX2 gene. Clinicians will have to manage any patient confusion or anxiety within the current 
193 uncertainty until more data is available. When designing future NGS DSD panels it will remain 
194 important to recognise that increasing the number of genes, especially those with limited data, will 
195 generate greater numbers of VOUS with increased cost and complexity of analysis.  This should be 
196 balanced against the potential for gene discovery. 
197
198 Segregation studies have been helpful in determination of pathogenicity in several families, as 
199 illustrated by patient 23, who had an Androgen Receptor (AR) variant initially reported as a VOUS. 
200 The patients older brother, previously shown to have a 47,XXY karyotype and a milder phenotype 
201 was subsequently shown to have the same AR variant. Given his additional X chromosome, without 
202 skewed X inactivation a milder phenotype would be expected. This increased our confidence in calling 
203 the variant a likely pathogenic mutation and highlights the importance of reviewing interpretation of 
204 variants when new information becomes available.
205
206 NGS technology has also allowed the identification of mosaic mutations in the AR gene, which may 
207 have gone undetected by other methods. Identification of an accurate number of reads enhances our 
208 knowledge of the level of mosaicism present. It should be noted, however, that the results represent 
209 the mutation load in peripheral blood (70% patient 8 and 30% patient 24) and not necessarily other 
210 relevant tissues. Of the mutations identified, both had been previously reported in non-mosaic form in 
211 the literature17,18. Mosaic mutations have however been reported in the AR gene19,20 and taken 
212 together with the clinical features, allowed us to conclude that these mutations in mosaic form were 
213 likely to be contributing to the phenotype in these patients. Importantly for patient management, AR 
214 mutations in mosaic form are believed to pose a risk of virilisation in patients due to the presence of 
215 wild type androgen receptor19. Distinguishing mosaic from non-mosaic forms therefore can have 
216 significant consequences for patient management and genetic recurrence risk.  
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8217
218 Identifying the correct genetic diagnosis modifies the patient management and impacts on the 
219 accuracy of information and choices available to family members. The former is clearly illustrated in 
220 case 21 where mutations in two different DSD related genes were present in the same family; 
221 HSD17B3 and AR. The family were requesting gonadectomy pre-adolescence in a 46,XY DSD 
222 female, on the basis that her cousins who were 46,XY DSD females, due to a homozygous HSD17B3 
223 mutations, had virilised and been managed with gonadectomy in another centre. Identification of a 
224 previously unidentified mutation in AR in this family meant 3 girls with 46,XY changed their 
225 subsequent management.  In 4 cases the diagnosis in affected siblings has been confirmed (listed in 
226 table 3 patients 7, 17, 21 & 23) including cases enabling early prenatal (patient 20) or neonatal 
227 (patient 17) diagnosis, and thus implementation of appropriate management from birth. This highlights 
228 the importance of identifying the molecular diagnosis not only for the proband but also for the wider 
229 family.
230 The panel also identified pathogenic mutations which were thought to be co-incidental and not to be 
231 related to the initial clinical presentation in the proband. In patient 18 with Congenital Adrenal 
232 Hyperplasia (CAH) due to HSD3B2 deficiency, the patient was also shown to be a carrier for the 
233 common splice mutation c.964-1G>C in the DHCR7 gene which is linked to Smith Lemli Opitz 
234 syndrome (SLOS). Whilst such incidental findings can be challenging for patient counselling, the 
235 information provided may also be of great significance.  This will be especially true when previously 
236 undetected autosomal recessive mutations are uncovered in highly consanguineous families, which 
237 are common within many DSD cohorts.
238
239 Where a clinician has a strong suspicion of the involvement of a specific gene, Sanger  sequencing 
240 may be more cost effective, especially where the number of amplicons is relatively small.  For 
241 example pathogenic mutations in the AMH, AMHR2, AR and SRD5A2 gene were identified in this 
242 way. When the original clinical diagnosis is incorrect however, the potential cost savings rapidly 
243 disappear if sequential Sanger sequencing is required, and therefore any benefit is highly dependent 
244 on the clinical expertise and the specificity of the additional non-genetic investigations.  There may 
245 also be atypical presentations not yet recognised for mutations in some genes, and therefore a wider 
246 panel approach has the potential to address this.
247
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9248 Despite the diagnostic rate of 25/73 for 46,XY DSD, the failure to achieve a diagnosis in 55 patients 
249 confirms the need for further development. Of note, the panel cannot currently detect copy number 
250 changes (CNVs), and so further development should include detection of CNVs that are below the 
251 resolution of the current chromosomal microarray assay.  The 30 genes in our panel were selected 
252 due to published evidence of their involvement in DSD, but new gene discoveries in studies such as 
253 the 100,000 genome project16 should enhance the diagnostic utility, especially for 46,XX DSD. Eggers 
254 et al demonstrated a 118/278  diagnostic rate for 46,XY DSD patients by including 64 DSD genes11, 
255 and Dong et al reported a 6/13 rate by including 219 genes10, thus diagnostic capability may be 
256 improved by increasing the gene number. These benefits may be marginal however as only one likely 
257 pathogenic mutation in the Dong series was in the additional 179 genes not included in this 30 gene 
258 panel. Comparison of these studies could indicate that a greater impact on the detection rate may be 
259 due to patient selection. It will be important, therefore, that further candidate gene inclusion is critically 
260 evaluated as the addition of genes without clear clinical utility will likely result in increasing cost and 
261 numbers of VOUS without necessarily increasing diagnostic capability. The future of this investigative 
262 pathway may well be transformed by implementation of whole exome or whole genome sequencing, 
263 but any benefits of diagnostic detection will have to be weighed against increased cost and clinical 
264 complexities resulting from VOUS and co-incidental findings. It therefore remains important to 
265 optimise such NGS panels for DSD so that a valid comparison can be made in future.
266
267 This data demonstrates clear advantages of an NGS panel approach for highly heterogenous 
268 conditions such as DSD. Despite the limitations of the panel including incomplete coverage and 
269 inability to detect copy number changes, the results presented here demonstrate that an NGS based 
270 panel approach is a useful frontline tool for diagnosing DSDs. In addition to a diagnostic yield of at 
271 least 25/80 we have shown examples of cases where the information provided from the panel has 
272 identified diagnoses in complex families with the potential for multiple aetiologies, cases where panel 
273 findings have significantly impacted management and treatment decisions, and examples of novel 
274 variants being identified, thus expanding our current knowledge. As more and more patients are 
275 tested, the information provided by such panels will continue to grow and improve our understanding 
276 of these complex conditions and hopefully improve the diagnostic capability of such tests. Despite its 
277 limitations, the clinical benefit of this approach is clearly demonstrated for DSD patients allowing for 
278 timely accurate diagnoses, more informed management strategies and improved counselling for 
279 patients and their families. 
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356 Figure 1: Summary of findings of DSD panel. 
357 Results of the panel are separated by karyotype (XX or XY) and by result. Diagnosis 
358 confirmed indicates patients where a pathogenic variant was detected compatible with the 
359 patients phenotype. VOUS (Variant Of Uncertain Significance) only indicates solely Class 3 
360 variants were detected and therefore a diagnosis could not be confirmed. No mutation 
361 indicates only Class 1 (polymorphisms) or Class 2 variants (unlikely to be pathogenic) were 
362 detected. 
363
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1Table 1a
Table 1: Genes included in the DSD panel
A summary of all genes and their chromosomal location which are included in the panel for both 46,XY 
DSD (table 1a) and 46,XX DSD (table 1b). CAG repeat in AR not analysed to avoid incidental diagnosis 
of Spinal bulbar muscular atrophy.
46,XY DSD Gene Name Location
ARX Xp22.13
ATRX Xq13.3
CBX2 17q25
DHH 12q13.1
DMRT1 9p24.3
MAMLD1 Xq28
NR0B1 Xp21.3
NR5A1 9q33
SOX9 17q24-q25
SRY Yp11.3
TSPYL1 6q22-23
WNT4 1p35
Disorders of 
testicular 
development
WT1 11p13
AMH
19p13.3-
p13.2
AMHR2 12q13
AR Xq11-q12
CYB5A 18q23
CYP11A1 15q23-24
CYP17A1 10q24.3
DHCR7 11q12-q13
HSD3B2 1p13.1
HSD17B3 9q22
LHCGR 2p21
POR 7q11.2
SRD5A2 2p23
Disorders of 
Hormone 
synthesis or 
action
StAR 8p11.2
46,XX DSD Gene Name Location
RSPO1 1p34.3
SOX9 17q24
SRY Yp11.3
Disorders of 
ovarian 
development
WNT4 1p35
CYP11B1 8q21-q22
CYP19A1 15q21
HSD3B2 1p13  
NR3C1 5q31
Androgen 
Excess
POR 7q11.2
Table 1b
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1Variant class Variant description Confirmation by Sanger Reported
1 Polymorphism No No
2 Unlikely to be pathogenic No Yes 
3 Variant of uncertain significance (VOUS) Yes Yes 
4 Likely to be pathogenic Yes Yes 
5 Clearly pathogenic Yes Yes 
Table 2  Classification and follow up of variants. All variants determined to be class 3-5 were 
confirmed using Sanger sequencing and all were included in the clinical reports. Variants considered to 
be unlikely to be pathogenic (class 2) were not confirmed by Sanger sequencing and were recorded for 
information only in the clinical report. Class 1 variants were not reported.
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1Pent S Reason for referral Gne Allele 1 Allele 2 Rs reported and follow up
1 XY M ?PAIS AR c.2402C>T p.(Thr801Ile) Confirmed diagnosis of PAIS.
2 XY M ?PMDS AMH c.283C>T p.(Arg95*) c.905G>A p.(Arg302Gln) Consistent with diagnosis of PMDS.
3 XY F ?46,XY DSD NR5A1 c.1171A>T p.(Lys391*) Normal Consistent with a diagnosis of a 46,XY DSD. Novel mutation.
4 XYp F ?46,XY DSD HSD17B3 c.614T>A p.(Val205Glu) c.645A>T p.(Glu215Asp) Supports diagnosis of 46,XY DSD due to HSD17B3 deficiency.
5 XYp F ?46,XY DSD HSD17B3 c.194C>T p.(Ser65Leu) c.729_735del7 p.(Ile244Argfs*11) Supports diagnosis of 46,XY DSD due to HSD17B3 deficiency.
6 XYp M ?46,XY DSD SRD5A2 c.698+1G>T c.698+1G>T Consistent with diagnosis of 46,XY due to SRD5A2 deficiency. 
7 XYp M X-linked hypospadias MAMLD1 c.1366C>T p.(Arg456*)
Consistent with MAMLD1 associated hypospadias. Confirmed in 2 affected 
brothers and mother (carrier).  Carrier of PMDS (c.35T>G p.(Val12Gly) in 
AMH).
8 XYp M ?46,XY DSD AR c.2391G>A p.(Trp797*) Mosaic (70% of reads). Likely causally related to clinical features.
9 XY F ?XY DSD NR5A1 c.69 C>A p.(Tyr23*) Normal Consistent with diagnosis of 46,XY DSD. Novel mutation.
10 XY F ?46,XY DSD HSD17B3 c.695C>T p.(Ser232Leu) c.695C>T p.(Ser232Leu) Confirms diagnosis 46,XY DSD due to HSD17B3 deficiency.
11 XYp M ?PMDS AMHR2
c.813_817delGCTCT, 
p.(Leu272Trpfs*24)
c.931G>A, p.(Gly311Ser) Consistent with features of PMDS. Novel mutation and novel variant.
12 XY F ?46,XY DSD SRD5A2 c.737G>A, p.(Arg246Gln) c.737G>A, p.(Arg246Gln) Consistent with diagnosis of SRD5A2 deficiency.
13 XYp M Penoscrotal hypospadias SRD5A2 c.586G>A, p.(Gly196Ser) c.586G>A, p.(Gly196Ser) Consistent with diagnosis of SRD5A2 deficiency assuming XY.
14 XY M
Gynaecomastia, 
Hypospadias, micropenis
AR c.2057T>C p.(Val686Ala) Consistent with clinical features. Confirmed inherited from mother.
15 XY M Ambiguous genitalia HSD17B3 c.277+4A>T c.133C>T p.(Arg45Trp) Consistent with clinical features. c.13C>T p.(Arg45Trp) is novel variant.
16 XY F ?AIS AR c.2343G>A p.(Met 781Ile) Consistent with diagnosis of AIS.
17 XY M ?PMDS AMHR2 c.289C>T p.(Arg97*) c.289C>T p.(Arg97*)
Confirms diagnosis of PMDS. Both parents carriers. Also had another child 
affected child who was homozygous for the same mutation (detected in 
neonatal period).
18 XY M ?XY DSD HSD3B2 c.518T>G p.(Leu173Arg) c.518T>G p.(Leu173Arg)
Confirms diagnosis of CAH due to HSD3B2 deficiency. Both parents are 
carriers. Patient also a carrier of the c.964-1G>C splice mutation in DHCR7.
19 XYp F ?46, XY DSD HSD17B3 c.277+4A>T c.645A>T p.(Glu215Asp)
Confirmed diagnosis of 46, XY DSD due to 17-Beta Hydroxysteroid 
dehydrogenase deficiency. Each parent carries 1 mutation.
20 XY M Undervirilised male SRD5A2 c.307C>T p.(Arg103*) c.107A>G, p.(His36Arg)
Consistent with clinical features. Parental samples confirmed compound 
heterozygous. Follow up biochemical testing confirmed SRD5A2 deficiency. 
Novel variant. 
21 XY F ?XY DSD AR c.2407dupC p.(Gln803Profs*27)
Confirms diagnosis of AIS. Two affected siblings also have mutation.
Novel mutation. Also heterozygous for HSD17B3 familial mutation.
c.803G>A p.(Cys268Tyr).
22 XY M Ambiguous genitalia WT1 c.1087A>T p.(Arg363*) Normal
May be contributing to features. Confirmed de-novo. Tumour screening 
initiated.
23 XY M Severe hypospadias AR c.2384T>A p.(Phe795Tyr)
Initially reported as VOUS. Once identified in affected (milder) brother 
whos karyotype was 47,XXY more confident that linked to features. Novel 
variant.
24 XY M
Severe hypospadias and
penile transposition
AR c.2645T>C p.(Leu882Pro) Mosaic (30% of reads). Likely causally related to phenotype.
25 XY M ?PMDS AMH c.649C>T p.(Gln217*) c.649C>T p.(Gln217*) Consistent with diagnosis of PMDS. Novel mutation.
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2detai ed olecular 
Details of mutations and variants found in patient reported with a confirmed molecular 
diagnosis. Details of the karyotypic and phenotypic sex are in the second column with M and F 
representing phenotypic sex. P indicates presumed karyotype (reports not seen) from SRY 
sequence reads. Pathogenic mutations linked to the diagnoses listed in gene column. Allele 1 
and 2 describe the mutations in the different alleles, a black box indicates an absent second X 
allele in XY individuals. Green = Normal (wildtype), Yellow = Class 3 variant (Variant Of 
Uncertain Significance (VOUS)), Orange = Class 4 variant (Likely pathogenic), Red = Class 5 
variant (Clearly pathogenic). AIS = Androgen Insensitivity Syndrome, CAH = Congenital Adrenal 
Hyperplasia, PAIS = Partial Androgen Insensitivity Syndrome, PMDS = Persistent Mullerian 
Duct Syndrome.
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1        	
e 4a: Patients  Variants  rtai ng	c en ere a diagss was no ted 
Patient ﬀﬁ ﬂﬀﬃ!" #or re#ﬀrral $ﬀne Allele 1 Allele 2 ﬂﬀ%&'s reported a"( #!&low up
)* XY ? N/A POR c.948-30G>A Normal A molecular diagnosis has not been confirmed
27 XYp M 1o gonadal failure, short stature WT1 c.11C>G, p.(Pro4Arg) Normal A molecular diagnosis has not been confirmed
28 XY M Mullerian resistant disorder HSD17B3 c.133C>T   p.(Arg45Trp) Normal A molecular diagnosis has not been confirmed
29 XY M ?46,XY DSD RSPO1 c.658C>T  p.(Arg220Trp) Normal A molecular diagnosis has not been confirmed
30 XY M Hypogonadism HSD3B2 c.809T>C  p.(Ile270Thr) Normal A molecular diagnosis has not been confirmed
CBX2 c.1411C>G  p.(Pro471Ala) Normal
31 XY F
Facial dysmorphism, gastric motility 
issues, undescended testes, 
adrenal insufficiency CBX2# c.616C>T  p.(Gln206*)  Normal
A molecular diagnosis has not been confirmed. #Variant found in 
alternative transcript.
32 XX M Hypospadias NR5A1 c.275G>A   p.(Arg92Gln) Normal A molecular diagnosis has not been confirmed
33 XY F ? Gonadal dysgenesis CYP11A1 c.1250T>G  p.(Val417Gly) Normal A molecular diagnosis has not been confirmed
CYP11A1 c.989C>T  p.(Thr330Met) Normal
34 XY F ? CYP11A1 imbalance
MAMLDI c.2009C>T  p.(Thr670Ile)  
A molecular diagnosis has not been confirmed
35 XY F Primary ovarian failure WT1 c.1493A>G  p.(Glu498Gly) Normal A molecular diagnosis has not been confirmed
CBX2 c.1416C>G  p.(Asp472Glu) Normal
36 XY M Severe penoscrotal hypospadias.
HSD3B2 c.500C>T  p.(Ala167Val) c.500C>T p.(Ala167Val)
A molecular diagnosis has not been confirmed
CBX2 c.1411C>G  p.Pro471Ala Normal
AMH c.53C>T  p.(Ala18Val) Normal37 XY F
Tall stature, uterus present, no 
obvious ovaries
AMH c.1556C>T  p.(Ala519Val) Normal
A molecular diagnosis has not been confirmed
38 XX F Premature ovarian failure CYP11B1 c.1451T>A  p.(Val484Asp) Normal A molecular diagnosis has not been confirmed
39 XY F Clitoromegaly, no vaginal opening AR c.1174C>T  p.(Pro392Ser)  Pathogenicity of variant uncertain due to conflicting evidence
40 XY M
Penoscrotal hypospadias, 
micropenis & undescended testes CBX2 c.785G>A  p.(Arg262Gln) Normal A molecular diagnosis has not been confirmed
CYP11A1 c.940G>A  p.(Glu314Lys) Normal
41 XY M
Hypospadias and penoscrotal 
transposition
HSD17B3 c.133C>T  p.(Arg45Trp) c.133C>T p.(Arg45Trp) 
A molecular diagnosis has not been confirmed
LHCGR c.828delC p.(Ser277Alafs*32) Normal
42 XY M ?46,XY DSD
CBX2 c.785G>A  p.(Arg262Gln) Normal
A molecular diagnosis has not been confirmed. Variant likely to be 
pathogenic but absence of second mutation leads to uncertain 
significance. 
43 XY M Ambiguous genitalia NR5A1 c.146G>A  p.(Cys49Tyr) Normal A molecular diagnosis has not been confirmed. De novo variant.
44 XYp F ?46,XY DSD NR5A1 c.1019C>T  p.(Ala340Val) Normal A molecular diagnosis has not been confirmed. Maternally inherited.
45 XY M Ambiguous genitalia
HSD17B3 c.202-22G>A c.202-22G>A 
A molecular diagnosis has not been confirmed. Recommend biochemical 
testing.
LHCGR c.458+3A>G Normal
46 XX F
Ambiguous genitalia, complete 
labial fusion
NR5A1 c.486C>T p.(=) Normal
A molecular diagnosis has not been confirmed
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2Patient +,- .,/013 4or re4,rral 5,ne Allele 1 Allele 2 .,0678s reported a39 417low up
ATRX c.2595C>G p.(His865Gln)  
3 XY F ?46,XY DSD
AMH c.-2C>T Normal
ATRX & AMH variants found in in addition to NR5A1 class 4 mutation (table 3).
4 XY F ? 46,XY DSD MAMLD1 c.2744A>C p.(Asp915Ala)  MAMLD1 variant found in addition to HSD17B3 mutations (table 3)
AMH c.35T>G p.(Val12Gly) Normal
AMH c.-74C>G Normal7 XY M X-linkedhypospadias
CBX2 c.565G>A p.(Ala189Thr) Normal
AMH & CBX2 variants found in addition to MAMLD1 class 4 mutation (table 3)
19 XY F ?46,XY DSD MAMLD1 c.728G>A p.(Cys243Tyr Normal MAMLD1 variant found in addition to HSD17B3 mutations (table 3)
22 XY M Ambiguous genitalia ATRX c.546A>G p.(=) Normal ATRX variant found in addition to WT1 mutation (table 3)
T:;le 4;b <:=>ents with ?:@>:Ats of BAcertain C>iA>ficance DhE@E a d>:iAosiF h:F ;eEA HIAf>@Jed.
K/Lle 4M Netails o4 Variants o4 O3certain +QU3Q4QV/3V, WXYO+Z Qdenti4ied.
Details of all VOUS found in this study. Table 4a indicates patients where only VOUS were found i.e. no pathogenic or likely pathogenic variants were 
identified. As such a diagnosis could not be confirmed in these patients. Table 4b indicates patients where VOUS were found in addition to the 
pathogenic/likely pathogenic mutations which were believed to be causative of the patients phenotype. Details of the karyotypic and phenotypic sex are in 
the second column with M and F representing phenotypic sex. P indicates presumed karyotype (reports not seen) from SRY sequence reads. Allele 1 and 2 
describe the variants in the different alleles, a black box indicates an absent second X allele in XY individuals. Green = Normal (wildtype), Yellow = Class 3 
variant (Variant Of Uncertain Significance (VOUS)), Red = Class 5 variant (Clearly pathogenic). 
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1Table Summary of the frequency of mutations and variants of uncertain significance 
found for each gene.
total er of pathogenic mutations (class 4 and 5 variants) and Variants of Uncertain 
Significance (VOUS, class 3) variants identified in the patients tested.  mutated allele is 
given a score of 1 therefore a patient homozygous for a pathogenic mutation (score=2) would 
y represented in the le as a patient who is compound heterozygous for 2 
pathogenic mutations.  
[\ne ]^_`ogenic
(Class 4 or 5)
VOUS
Class (3)
Gene Pathogenic 
(Class 4 or 5)
VOUS
AMH 3 3 HSD3B2 2 3
AMHR2 3 1 LHCGR 1 1
AR 7 1 MAMLD1 1 1
ARX 0 0 NR0B1 0 0
ATRX 0 0 NR3C1 0 0
CBX2 0 a NR5A1 2 4
CYB5A 0 0 POR 0 1
CYP11A1 0 3 RSPO1 0 1
CYP11B1 0 1 SOX9 0 0
CYP17A1 0 0 SRD5A2 7 1
CYP19A1 0 0 SRY 0 0
DHCR7 1 0 STAR 0 0
DHH 0 0 TSPYL1 0 0
DMRT1 0 0 WNT4 0 0
HSD17B3 9 a WT1 1 2
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1Paper
Numcer 
od jknes 
in panel
Numcer od
patients tested 
and karyotypic sex
Diagnostic 
Yield
Overall
Diagnostic 
Yield
46,XY
Diagnostic 
Yield
46,XX
Baxter, 2015 (ref 9) 64 40 XY - 14/40 -
Dong, 2016 (ref 10) 219 13 XY, 8 XX 8/21* 6/13 2/8 
Eggers, 2016 (ref 11) 64 278 XY, 48 XX 126/326 118/278 8/48 
Kim, 2017 (ref 12) 67 37 XY, 7 XX 13/44 13/37 0/7 
Hughes, 2018 30 73 XY, 7 XX 25/80 25/73 0/7 
ies using NGS analysis for DSDs
g et al report their detection rate of DSD as however 3 of these patients had 
Variants of Uncertain Significance (VOUS) only and therefore using the same parameters as 
in this study a diagnosis would not be confirmed. Numbers modified above to allow more 
accurate comparison with this study. 
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